Dyslipidaemia

24 Dyslipidaemia





Key points











Disorders of lipoprotein metabolism together with high fat diets, obesity and physical inactivity have all contributed to the current epidemic of atherosclerotic disease seen in developed countries. Disorders of lipoprotein metabolism that result in elevated serum concentrations of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) increase the risk of an individual developing cardiovascular disease (CVD). In contrast, high-density lipoprotein cholesterol (HDL-C) confers protection against CVD, with the risk reducing as HDL-C increases. It is, therefore, clear that the term hyperlipidaemia, which was formerly used to describe disorders of lipoprotein metabolism, is inappropriate. It is more appropriate to use the term dyslipidaemia, which encompasses both abnormally high levels of specific lipoproteins, for example, LDL-C, and abnormally low levels of other lipoproteins, for example, HDL-C, as well as disorders in the composition of the various lipoprotein particles. It is particularly appropriate when considering the individual at risk of CVD with a normal or high TC and low HDL-C (total cholesterol:HDL-C ratio).



Epidemiology


Lipid and lipoprotein concentrations vary among different populations, with countries consuming a Western type of diet generally having higher TC and LDL-C levels than those where regular consumption of saturated fat is low.


The ideal serum lipid profile is unknown and varies between different populations, even across Europe, and also within a given population. For practical purposes the values presented in Table 24.1 represent the target levels for TC and LDL-C in the UK for adults receiving treatment for secondary prevention of CVD. For completeness, the values for triglycerides and HDL-C are also presented, although the benefit of achieving the stated targets is less clear.


Table 24.1 Optimal serum lipid profile

















Total cholesterol (TC)a <4.0 mmol/L
LDL cholesterol (LDL-C)a <2.0 mmol/L
Triglyceridesb <1.7 mmol/L
HDL cholesterol (HDL-C) >1.0 mmol/L in men
>1.2 mmol/L in women

a Target levels in individuals with established atherosclerotic disease, coronary heart disease, stroke, peripheral arterial disease, diabetes mellitus or where there is a cardiovascular disease risk >20% over 10 years. In these identified individuals, the aim is to achieve the value stated in the table or a 25% reduction in total cholesterol and a 30% reduction in LDL-C from their baseline levels should these set target levels lower than those stated in the table.


b Fasting levels.


Despite a 50% reduction in the death rate from CVD over the past 25 years, it remains the leading cause of premature death and morbidity in the UK (British Heart Foundation, 2008), and the higher the levels of TC in an individual the greater the chance of developing CVD. At the individual level there appears no level below which a further reduction of TC or LDL-C is not associated with a lower risk of CVD. The death rate from CVD is threefold higher in males than females, but because women live longer and are at increased risk of stroke after the age of 75 years their lifetime risk of disease is greater (National Institute of Health and Clinical Excellence, 2008a).


TC levels tend to increase with age such that 80% of British men aged 45–64 years have a level that exceeds 5 mmol/L and the population average is 5.6 mmol/L. In contrast, in rural China and Japan, the average is 4 mmol/L.


Population-based approaches to vascular screening have the potential to provide significant health gain for society as most deaths from CVD occur in individuals who are not yet identified as at increased risk. Moreover, a small reduction in average population levels of TC and LDL-C can potentially prevent many deaths. In England, a scheme was introduced in 2009 for everyone between 40 and 74 years of age to receive a free health check to include measurement of TC and the TC:HDL-C ratio. The intention was that individuals would be given the necessary information about their health to make changes to lifestyle and avoid preventable disease.



Lipid transport and lipoprotein metabolism


The clinically important lipids in the blood (unesterified and esterified cholesterol and triglycerides) are not readily soluble in serum and are rendered miscible by incorporation into lipoproteins. There are six main classes of lipoproteins: chylomicrons, chylomicron remnants, very low-density lipoproteins (VLDL-C), intermediate-density lipoproteins (IDL-C), low-density lipoproteins (LDL-C) and high-density lipoproteins (HDL-C).


The protein components of lipoproteins are known as apoproteins (apo), of which apoproteins A-I, E, C and B are perhaps the most important. Apoprotein B exists in two forms: B-48, which is present in chylomicrons and associated with the transport of ingested lipids, and B-100, which is found in endogenously secreted VLDL-C and associated with the transport of lipids from the liver (Fig. 24.1).



When dietary cholesterol and triglycerides are absorbed from the intestine they are transported in the intestinal lymphatics as chylomicrons. These are the largest of the lipoprotein particles of which triglycerides normally constitute approximately 80% of the lipid core. The chylomicrons pass through blood capillaries in adipose tissue and skeletal muscle where the enzyme lipoprotein lipase is located, bound to the endothelium. Lipoprotein lipase is activated by apoprotein C-II on the surface of the chylomicron. The lipase catalyses the breakdown of the triglyceride in the chylomicron to free fatty acid and glycerol, which then enter adipose tissue and muscle. The cholesterol-rich chylomicron remnant is taken up by receptors on hepatocyte membranes, and in this way dietary cholesterol is delivered to the liver and cleared from the circulation.


VLDL-C is formed in the liver and transports triglycerides, which again make up approximately 80% of its lipid core, to the periphery. The triglyceride content of VLDL-C is removed by lipoprotein lipase in a similar manner to that described for chylomicrons above, and forms IDL-C particles. The core of IDL-C particles is roughly 50% triglyceride and 50% cholesterol esters, acquired from HDL-C under the influence of the enzyme lecithin-cholesterol acyltransferase (LCAT). Approximately 50% of the body’s IDL particles are cleared from serum by the liver. The other 50% of IDL-C are further hydrolysed and modified to lose triglyceride and apoprotein E1 and become LDL-C particles. LDL-C is the major cholesterol-carrying particle in serum.


LDL-C provides cholesterol, an essential component of cell membranes, bile acid and a precursor of steroid hormones to those cells that require it. LDL-C is also the main lipoprotein involved in atherogenesis, although it only appears to take on this role after it has been modified by oxidation. For reasons that are not totally clear, the arterial endothelium becomes permeable to the lipoprotein. Monocytes migrate through the permeable endothelium and engulf the lipoprotein, resulting in the formation of lipid-laden macrophages that have a key role in the subsequent development of atherosclerosis. The aim of treatment in dyslipidaemia is normally to reduce concentrations of LDL-C (and consequently atherogenesis) and thus reduce TC at the same time.


While VLDL-C and LDL-C are considered the ‘bad’ lipoproteins, HDL-C is often considered to be the ‘good’ antiatherogenic lipoprotein. In general, about 65% of TC is carried in LDL-C and about 25% in HDL.




Reverse cholesterol transport pathway


The reverse cholesterol transport pathway (Fig. 24.2) controls the formation, conversion, transformation and degradation of HDL-C and is the target site for a number of new, novel drugs and has recently been described (Chapman et al., 2010).


image

Fig. 24.2 Pathways of reverse cholesterol transport in man (Chapman et al., 2010 with kind permission from Oxford University Press, Oxford).


The reverse cholesterol transport system involves lipoprotein-mediated transport of cholesterol from peripheral, extra-hepatic tissues and arterial tissue (potentially including cholesterol-loaded foam cell macrophages of the atherosclerotic plaque) to the liver for excretion, either in the form of biliary cholesterol or bile acids. The ATP-binding cassette transporters, ABCA1 and ABCG1, and the scavenger receptor B1, are all implicated in cellular cholesterol efflux mechanisms to specific apoA-1/HDL acceptors. The progressive action of lecithin:cholesterol acyl transferase on free cholesterol in lipid-poor, apolipoprotein A-I-containing nascent high-density lipoproteins, including pre-β-HDL, gives rise to the formation of a spectrum of mature, spherical high-density lipoproteins with a neutral lipid core of cholesteryl ester and triglyceride. Mature high-density lipoproteins consist of two major subclasses, large cholesteryl ester-rich HDL2 and small cholesteryl ester-poor, protein-rich HDL3 particles; the latter represent the intravascular precursors of HDL2. The reverse cholesterol transport system involves two key pathways: (a) the direct pathway (blue lines), in which the cholesteryl ester content (and potentially some free cholesterol) of mature high-density lipoprotein particles is taken up primarily by a selective uptake process involving the hepatic scavenger receptor B1 and (b) an indirect pathway (dotted blue lines) in which cholesteryl ester originating in HDL is deviated to potentially atherogenic VLDL, IDL and LDL particles by cholesteryl ester transfer protein. Both the cholesteryl ester and free cholesterol content of these particles are taken up by the liver, predominantly via the LDL receptor which binds their apoB100 component. This latter pathway may represent up to 70% of cholesteryl ester delivered to the liver per day. The hepatic LDL receptor is also responsible for the direct uptake of high-density lipoprotein particles containing apoE; apoE may be present as a component of both HDL2 and HDL3 particles, and may be derived either by transfer from triglyceride-rich lipoproteins, or from tissue sources (principally liver and monocyte-macrophages). Whereas HDL uptake by the LDL receptor results primarily in lysosomal-mediated degradation of both lipids and apolipoproteins, interaction of HDL with scavenger receptor B1 regenerates lipid-poor apoA-I and cholesterol-depleted HDL, both of which may re-enter the HDL/apoA-I cycle.


From the above it is evident that HDL-C plays a major role in maintaining cholesterol homeostasis in the body. As a consequence it is considered desirable to maintain both levels of the protective HDL-C and the integrity of the reverse cholesterol transport pathway. Low levels of HDL-C are found in 17% of men and 5% of women and may be a risk factor for atherogenesis that is comparable in importance to elevated levels of LDL-C. Drugs that reduce HDL-C levels are considered to have an undesirable effect on lipid metabolism and increase the risk of developing CVD.




Aetiology



Primary dyslipidaemia


Up to 60% of the variability in cholesterol fasting lipids may be genetically determined, although expression is often influenced by interaction with environmental factors. The common familial (genetic) disorders can be classified as:






Familial hypercholesterolaemia


Heterozygous familial hypercholesterolaemia (often referred to as FH) is an inherited metabolic disease that affects approximately 1 in 500 of the population. In the UK, this represents about 110,000 individuals. Familial hypercholesterolaemia is caused by a range of mutations, which vary from family to family, in genes for the pathway that clear LDL-C from the blood. The most common mutation affects the LDL receptor gene. Given the key role of LDL receptors in the catabolism of LDL-C, patients with FH may have serum levels of LDL-C two to three times higher than the general population. It is important to identify and treat these individuals from birth, otherwise they will be exposed to high concentrations of LDL-C and will suffer the consequences. Familial hypercholesterolaemia is transmitted as a dominant gene, with siblings and children of a parent with FH having a 50% risk of inheriting it. It is important to suspect FH in people that present with TC >7.5 mmol/L, particularly where there is evidence of premature CV disease within the family. Guidance on diagnosis, identifying affected relatives and management are available but it is important to seek specialist advice for this group of high-risk patients (National Institute of Health and Clinical Excellence, 2008b).


In patients with heterozygous FH, CVD presents about 20 years earlier than in the general population, with some individuals, particularly men, dying from atherosclerotic heart disease often before the age of 40 years. The adult heterozygote typically exhibits the signs of cholesterol deposition such as corneal arcus (crescentic deposition of lipids in the cornea), tendon xanthoma (yellow papules or nodules of lipids deposited in tendons) and xanthelasma (yellow plaques or nodules of lipids deposited on eyelids) in their third decade.


In contrast to the heterozygous form, homozygous FH is extremely rare (1 per million) and associated with an absence of LDL receptors and almost absolute inability to clear LDL-C. In these individuals, involvement of the aorta is evident by puberty and usually accompanied by cutaneous and tendon xanthomas. Myocardial infarction has been reported in homozygous children as early as 1.5–3 years of age. Up to the 1980s, sudden death from acute coronary insufficiency before the age of 20 years was normal.








Secondary dyslipidaemia


Dyslipidaemias that occur secondary to a number of disorders (Box 24.1), dietary indiscretion or as a side effect of drug therapy (Table 24.2) account for up to 40% of all dyslipidaemias. Fortunately, the lipid abnormalities in secondary dyslipidaemia can often be corrected if the underlying disorder is treated, effective dietary advice implemented or the offending drug withdrawn.




On occasion, a disorder may be associated with dyslipidaemia but not the cause of it. For example, hyperuricaemia (gout) and hypertriglyceridaemia co-exist in approximately 50% of men. In this particular example, neither is the cause of the other and treatment of one does not resolve the other. There are, however, two notable exceptions to the rule with this example: nicotinic acid and fenofibrate. Both drugs reduce triglyceride levels but nicotinic acid increases urate levels while fenofibrate reduces them by an independent uricosuric effect.


Some of the more common disorders that cause secondary dyslipidaemias include the following.



Diabetes mellitus


Premature atherosclerotic disease is the main cause of reduced life expectancy in patients with diabetes. The atherosclerotic disease is often widespread and complications such as plaque rupture and thrombotic occlusion occur more often and at a younger age. The prevalence of CHD is up to four times higher among diabetic patients with more than 80% likely to die from a cardiovascular event. LDL levels are a stronger predictor of CV risk in diabetic patients than blood glucose control or blood pressure.




Type 2 diabetes


Patients with type 2 diabetes typically have increased triglycerides and decreased HDL-C. Levels of TC may be similar to those found in non-diabetic individuals but the patient with type 2 diabetes often has increased levels of highly atherogenic small dense LDL particles.


Individuals with type 2 diabetes and aged over 40 years, but without CVD, are often considered to have the same cardiovascular risk as patients without diabetes who have survived a myocardial infarction. This assumption is generally appropriate but influenced by patient age, duration of diabetes and gender and holds better for women than men. This probably occurs because the impact of type 2 diabetes is more marked in women than men. In some guidelines, the criteria for at risk is age above 40 years but with one other risk factor present, for example, hypertension, obesity, smoker, etc.


National Institute of Health and Clinical Excellence (2008a) consider an individual with type 2 diabetes to be at high premature cardiovascular risk for their age unless he or she:









Where the individual is found to be at risk the patient is typically started on 40 mg simvastatin (or equivalent generic statin). Current guidance indicates the dose can be titrated up to simvastatin 80 mg a day if lipid levels are not reduced to less than 4 mmol/L for TC and less than 2 mmol/L for LDL-C on 40 mg simvastatin. In those who do not reach target with 80 mg simvastatin, 80 mg atorvastatin may be tried. However, with both drugs at the higher dose there is increasing concern about their side effect profile and consequently use is limited at these doses.


Individuals aged 18–39 with type 2 diabetes may also be at high risk and in need of treatment with a statin. Again at-risk individuals typically receive 40 mg simvastatin, or equivalent alternate statin, a day titrated up to 80 mg a day if levels for TC of less than 4 mmol/L and less than 2 mmol/L for LDL-C are not achieved. Again there are emerging concerns about use of these higher doses.








Drugs


A number of drugs can adversely affect serum lipid and lipoprotein concentrations (see Table 24.2).



Antihypertensive agents


Hypertension is a major risk factor for atherosclerosis, and the beneficial effects of lowering blood pressure are well recognised. It is, however, a concern that, although treatment of patients with some antihypertensives has reduced the incidence of cerebrovascular accidents and renal failure, there has been no major impact in reducing the incidence of CHD. It has been suggested that some of these antihypertensive agents have an adverse effect on lipids and lipoproteins that override any beneficial reduction of blood pressure.









Risk Assessment



Primary prevention


In patients with no evidence of CHD or other major atherosclerotic disease, there are a number of CVD risk prediction charts, including those produced by the Joint British Societies (JBS2) (British Hypertension Society, 2009) for males (Fig. 24.3) and females (Fig. 24.4). JBS2 recommends that all adults from the age of 40 years, with no history of CVD or diabetes, and not receiving treatment for raised blood pressure or dyslipidaemia, should receive opportunistic screening every 5 years in primary care. The cardiovascular risk calculated using the JBS2 charts is based on the number of cardiovascular events expected over the next 10 years in 100 women or men with the same risk factors as the individual being assessed. Those with a cardiovascular risk >20% over 10 years are deemed to require treatment according to current national and international guidelines, although individuals with a risk as low as 8% over 10 years will gain some benefit, this will be small.



Jun 18, 2016 | Posted by in PHARMACY | Comments Off on Dyslipidaemia

Full access? Get Clinical Tree

Get Clinical Tree app for offline access